The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Open accessAbstract
New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This phase II trial evaluated the efficacy of Ipilimumab for advanced pancreatic cancer. Subjects were adults with locally advanced or metastatic pancreas adenocarcinoma with measurable disease, good performance status, and minimal comorbidities. Ipilimumab was administered intravenously (3.0 mg/kg every 3 wk; 4 doses/course) for a maximum of 2 courses. Response rate by response evaluation criteria in solid tumors criteria and toxicity were measured. Twenty-seven subjects were enrolled (metastatic disease: 20 and locally advanced: 7) with median age of 55 years (27 to 68 y) and good performance status (26 with Eastern Cooperative Oncology Group performance status =0 to 1). Three subjects experienced ≥ grade 3 immune-mediated adverse events (colitis:1, encephalitis:1, hypohysitis:1). There were no responders by response evaluation criteria in solid tumors criteria but a subject experienced a delayed response after initial progressive disease. In this subject, new metastases after 2 doses of Ipilimumab established progressive disease. But continued administration of the agent per protocol resulted in significant delayed regression of the primary lesion and 20 hepatic metastases. This was reflected in tumor markers normalization, and clinically significant improvement of performance status. Single agent Ipilimumab at 3.0 mg/kg/dose is ineffective for the treatment of advanced pancreas cancer. However, a significant delayed response in one subject of this trial suggests that immunotherapeutic approaches to pancreas cancer deserve further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Self-citationA Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Self-citationPancreatic Cancer: Adjuvant Combined Radiation and Chemotherapy Following Curative Resection
Kaiser, M. H. (1985) · Archives of Surgery · doi:10.1001/archsurg.1985.01390320023003 · Cited by 1,406
Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Self-citationKlinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M. L., Veenhof, C. H., Arnaud, J. P., Gonzalez, D. G., de Wit, L. T., Hennipman, A., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199912000-00006 · Cited by 1,286
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Self-citationDynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · cited 1×
“In this model, immunosuppressive cell types dominate early infiltrates and persist in invasive lesions.(22) In humans, a lymphocytic infiltrate predominates in the microenvironment of pancreatic adenocarcinoma, and T regulatory lymphocytes, which exert an immunosuppressive response to antigenic stimuli, comprise an ab…”
BackgroundCallery, M. P., Chang, K. J., Fishman, E. K., Talamonti, M. S., William Traverso, L., & Linehan, D. C. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0408-6 · Cited by 902
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Self-citationRegine, W. F., Winter, K. A., Abrams, R. A., Safran, H., Hoffman, J. P., Konski, A., Benson, A. B., Macdonald, J. S., Kudrimoti, M. R., Fromm, M. L., et al. (2008) · JAMA · doi:10.1001/jama.299.9.1019 · Cited by 755
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
Self-citationStudy Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., Nagakawa, T., & Nakayama, T. (2002) · Cancer · doi:10.1002/cncr.10831 · Cited by 631
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Self-citationJaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.145 · Cited by 600
National Failure to Operate on Early Stage Pancreatic Cancer
Bilimoria, K. Y., Bentrem, D. J., Ko, C. Y., Stewart, A. K., Winchester, D. P., & Talamonti, M. S. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180691579 · Cited by 554
Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 485
Self-citationKlapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 434
Self-citationSmall, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Self-citationBlansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Self-citationBakkevold, K. E., Arnesjø, B., Dahl, O., & Kambestad, B. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80349-1 · Cited by 338
Bernhardt, S. L., Gjertsen, M. K., Trachsel, S., Møller, M., Eriksen, J. A., Meo, M., Buanes, T., & Gaudernack, G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603437 · Cited by 305
Pancreatic Adenocarcinoma: The Actual 5-Year Survivors
Ferrone, C. R., Brennan, M. F., Gonen, M., Coit, D. G., Fong, Y., Chung, S., Tang, L., Klimstra, D., & Allen, P. J. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0384-8 · Cited by 251
Wobser, M., Keikavoussi, P., Kunzmann, V., Weininger, M., Andersen, M. H., & Becker, J. C. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0102-x · Cited by 162
Multiple Costimulatory Modalities Enhance CTL Avidity
Hodge, J. W., Chakraborty, M., Kudo‐Saito, C., Garnett‐Benson, C., & Schlom, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.5994 · Cited by 138
Toubaji, A., Achtar, M. S., Provenzano, M., Herrin, V. E., Behrens, R. J., Hamilton, M., Bernstein, S. A., Venzon, D. J., Gause, B. L., Marincola, F. M., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0477-6 · Cited by 122
Nukui, Y., Picozzi, V. J., & Traverso, L. W. (2000) · The American Journal of Surgery · doi:10.1016/s0002-9610(00)00369-x · Cited by 122
Rosenberg, S. A., Yang, J., White, D. E., & Steinberg, S. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68669-7 · Cited by 116
Self-citationIncreased Prevalence of Regulatory T Cells (Treg) is Induced by Pancreas Adenocarcinoma
Liyanage, U. K., Goedegebuure, P. S., Moore, T. T., Viehl, C. T., Moo‐Young, T. A., Larson, J. W., Frey, D. M., Ehlers, J. P., Eberlein, T. J., & Linehan, D. C. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000205644.43735.4e · Cited by 116
Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
Kaufman, H. L., Kim‐Schulze, S., Manson, K. H., DeRaffele, G., Mitcham, J., Seo, K.-S., Kim, D. W., & Marshall, J. L. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-60 · Cited by 116
Phase II Study of Anti–Gastrin-17 Antibodies, Raised to G17DT, in Advanced Pancreatic Cancer
Brett, B. T., Smith, S. C. L., Bouvier, C., Michaeli, D., Hochhauser, D., Davidson, B. R., Kurzawinski, T. R., Watkinson, A. F., van Someren, N., Pounder, R. E., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.151 · Cited by 109
Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients
Nisticò, P., Capone, I., Palermo, B., Bello, D. D., Ferraresi, V., Moschella, F., Aricò, E., Valentini, M., Bracci, L., Cognetti, F., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23886 · Cited by 105
Maki, R. G., Livingston, P. O., Lewis, J. J., Janetzki, S., Klimstra, D. S., DeSantis, D., Srivastava, P. K., & Brennan, M. F. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9205-2 · Cited by 100
Mechanisms Involved in Radiation Enhancement of Intratumoral Dendritic Cell Therapy
Teitz‐Tennenbaum, S., Li, Q., Okuyama, R., Davis, M. A., Sun, R., Whitfield, J. R., Knibbs, R. N., Stoolman, L. M., & Chang, A. E. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318163628c · Cited by 90
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
Royal, R. E., Steinberg, S. M., Krouse, R. S., Heywood, G., White, D. E., Hwu, P., Marincola, F. M., Parkinson, D. R., Schwartzentruber, D. J., Topalian, S. L., et al. (1996) · PubMed · Cited by 70
Self-citationTheoret, M. R., Arlen, P. M., Pazdur, M. P., Dahut, W. L., Schlom, J., & Gulley, J. L. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.017 · Cited by 11
Cited by
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
“Small proof-of-concept trials with ipilimumab have revealed some anecdotal responses (Royal et al., 2010), and our study suggests that stratifying patients on the basis of their fibrosis scores might offer better responses.”
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Metadata
- Authors
- Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., & Rosenberg, S. A.
- Venue
- Journal of Immunotherapy
- Published
- 2010-10
- Volume
- 33
- Issue
- 8
- Pages
- 828-833
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2044363258
- Cited by
- 1,257
- References
- 39
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.